HIMS stock has had a significant day, with some reports indicating it is on an upswing and others suggesting it was previously on a decline. The company's potential revenue from peptides is a point of interest, with some estimates suggesting it could drive up to $19 billion in annual revenue by 2030. An upcoming FDA review of peptides may be a catalyst for the stock's movement, with some analysts raising their targets for the company.